Quality of life after transcatheter or surgical aortic valve replacement using the Toronto Aortic Stenosis Quality of Life Questionnaire.

Autor:	Kennon S; Department of Cardiology, Barts Heart Centre, St Bartholomew's Hospital, London, UK., Styra R; Department of Psychiatry, University Health Network, Toronto, Ontario, Canada., Bonaros N; Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria., Stastny L; Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria., Romano M; Department of Thoracic and Cardiovascular Surgery, Hopital Prive Jacques Cartier, Massy, France., Lefèvre T; Institut Jacques Cartier, Massy, France., Di Mario C; Department of Structural Interventional Cardiology, Department of Cardiac Surgery, Careggi University Hospital, Florence, Italy., Stefàno P; Department of Structural Interventional Cardiology, Department of Cardiac Surgery, Careggi University Hospital, Florence, Italy., Ribichini FL; Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy., Himbert D; Department of Cardiology, Bichat-Claude Bernard Hospital, Paris, France., Urena-Alcazar M; Department of Cardiology, Bichat-Claude Bernard Hospital, Paris, France., Salgado-Fernandez J; Department of Cardiology, Department of Cardiovascular Surgery, Hospital Juan Canalejo, Coruna, Spain., Cuenca Castillo JJ; Department of Cardiology, Department of Cardiovascular Surgery, Hospital Juan Canalejo, Coruna, Spain., Garcia B; Department of Cardiology, Hospital Vall d'Hebron, CIBER CV, Barcelona, Spain., Deutsch C; Clinical Studies and Registries, Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany., Sykorova L; Medical Affairs, Edwards Lifesciences, Prague, Czech Republic., Kurucova J; Medical Affairs, Edwards Lifesciences, Prague, Czech Republic., Thoenes M; Medical Affairs, Edwards Lifesciences, Nyon, Switzerland., Lüske C; Clinical Studies and Registries, Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany., Bramlage P; Clinical Studies and Registries, Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany., Frank D; Department of Internal Medicine III (Cardiology, Angiology and Critical Care), Germany and DZHK (German Centre for Cardiovascular Research), Kiel, Germany derk.frank@uksh.de.
Jazyk:	angličtina
Zdroj:	Open heart [Open Heart] 2021 Nov; Vol. 8 (2).
DOI:	10.1136/openhrt-2021-001821
Abstrakt:	Background: The Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ) is a validated instrument for assessing quality of life (QoL) in patients with severe aortic stenosis (AS). In this study, we evaluated health status outcomes, based on the TASQ, in patients with severe AS undergoing transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Methods: The TASQ registry was a prospective observational registry. Patients with severe AS from nine centres in Europe and one in Canada underwent either SAVR or transfemoral TAVR. Patients completed the TASQ, Kansas City Cardiomyopathy Questionnaire and Short Form-12 V.2 prior to the intervention, predischarge, and at 30-day and 3-month follow-ups. Primary end point was the TASQ score. Results: In both the TAVR (n=137) and SAVR (n=137) cohorts, significant increases were observed in all three scores. The overall TASQ score improved as did all but one of the individual domains at 3 months after the intervention (p<0.001). TASQ health expectations were the only domain which worsened (p<0.001). Across TASQ subscores, significant changes were evident from the time of discharge in the TAVR and 30-day follow-up in the SAVR cohort. In a categorical analysis of the TASQ, 39.7% of the TAVR group and 35.0% of the SAVR group had a substantially improved health status at 3 months compared with baseline. Conclusions: The TASQ captured changes in QoL among patients with severe AS who were treated with TAVR or SAVR. QoL improved substantially after either intervention, as indicated by changes in the TASQ overall score at 3 months. Trial Registration Number: NCT03186339. Competing Interests: Competing interests: PB is the representative of the Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany. LS, JK and MT are employees of the funder. All centres were paid by IPPMed for the enrolment and documentation of patients. (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu